Hirofumi Shibata

Nov 20, 2023 | frontiersin.org | Takumi Kumai |Marc Oliva |Hirofumi Shibata

IntroductionThe treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was significantly advanced with introduction of the anti-EGFR antibody cetuximab (Cmab) in 2005 (1), and further improved with the advent of immune checkpoint inhibitors (ICIs) (2, 3). Among these, the anti-programmed cell death protein 1 (PD-1) antibodies pembrolizumab and nivolumab have become the standard systemic therapy for R/M SCCHN.